PHILADELPHIA, PA, UNITED STATES - Nov 12, 2018 - ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the addition of David Raunig, PhD to its team of scientific and technological imaging experts. The science team is a key component of ERT’s rapidly growing advanced technology imaging solution, which has been used in more than 500 clinical studies to date.

David brings 20+ years of experience integrating current medical, scientific and statistical techniques into the collection and analysis of imaging data during the development of new medical products. Previously, David held senior leadership positions with global pharmaceutical and clinical research organizations, including Bristol Myer-Squib, Icon Medical Imaging, and Pfizer.

“ERT’s innovative imaging solution is overcoming the challenges many drug developers face when using traditional imaging approaches to support safety and efficacy endpoints during clinical development,” said David Raunig. “I’m thrilled to join this team of forward-thinking scientists and to be part of the solution that delivers the highest quality imaging data to worldwide clinical trial sponsors and CROs.”

David is responsible for driving the quality of ERT’s imaging solution by integrating regulations, operations and statistics into the conduct of clinical trials. He joins an established scientific team who apply their 160 collective years of imaging experience to ensure ERT’s advanced technology imaging solution reduces human error, complies with global regulations, and accelerates clinical development.

“David’s significant experience in pharmaceutical research complements ERT’s expertise in managing our customers’ most complex imaging challenges and delivering greater efficiencies throughout clinical research,” said Tim Kulbago, Vice President, Imaging at ERT. “We’re pleased to welcome him to the ERT imaging team.”

For more information on ERT’s expert-driven, purpose-built imaging solution, visit ert.com/imaging.

###

About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.